secwatch.observer — SEC 8-K summary
======================================

Issuer:     REVELATION BIOSCIENCES, INC. (REVB)
CIK:        0001810560
Form:       8-K
Filed at:   2023-04-03T23:59:59+00:00
Accession:  0000950170-23-011612
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Revelation Biosciences reports FY2022 net loss $10.8M; cash $5.3M through June 2024
--------------------------------------------------------------------------------

- Cash and cash equivalents $5.3M at Dec 31, 2022 vs $1.3M year ago; $15.6M public offering completed.
- Net loss for FY2022 $10.8M ($20.09 per share) vs $12.0M ($42.50 per share) in 2021.
- Operating cash burn $11.2M for FY2022 vs $11.1M in prior year.
- Plans to start combined Phase 1a clinical study for REVTx-300 and REVTx-100 in H2 2023.
- Management believes cash sufficient to fund operations through June 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1810560/000095017023011612/0000950170-23-011612-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1810560/000095017023011612/revb-20230330.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-011612

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer